Stock 4502 TAKEDA PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Takeda Pharmaceutical Company Limited Stock Fukuoka Stock Exchange

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Fukuoka Stock Exchange
Other stock markets
 08:25:26 2024-04-16 pm EDT 		5-day change 1st Jan Change
4,080 JPY -1.21% Intraday chart for Takeda Pharmaceutical Company Limited -.--% +2.13%
03:02pm Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
04:21am Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes MT

Financials

Sales 2024 4,264B 27.03B Sales 2025 * 4,269B 27.06B Capitalization 6,345B 40.22B
Net income 2024 144B 913M Net income 2025 * 103B 653M EV / Sales 2024 2.57 x
Net Debt 2024 4,386B 27.8B Net Debt 2025 * 4,189B 26.55B EV / Sales 2025 * 2.47 x
P/E ratio 2024
45.4 x
P/E ratio 2025 *
62.6 x
Employees -
Yield 2024
4.49%
Yield 2025 *
4.8%
Free-Float 99.12%
More Fundamentals * Assessed data

Chart Takeda Pharmaceutical Company Limited

Dynamic Chart

Latest news about Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP MT
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes MT
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback DJ
Sector Update: Health Care Stocks Decline Premarket Monday MT
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell MT
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall MT
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints MT
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies DJ
Takeda's seizure drug fails to meet main goal in late-stage studies RE
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome CI
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome CI
Takeda Signs Option Agreement with Ascentage to License Leukemia Drug MT
Takeda Pharmaceutical Company Limited Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, Third-Generation BCR-ABL Tyrosine Kinase Inhibitor CI
Takeda Issues New Shares, Disposes of Treasury Shares Under Long-term Incentive Plan for Employees MT
Takeda Pharmaceutical Prices Second Hybrid Bonds for 460 Billion Yen MT
More news

Latest transcript on Takeda Pharmaceutical Company Limited

Logo Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited - Special Call
More transcripts

Analyst Recommendations on Takeda Pharmaceutical Company Limited

Toyota becomes Asia's most shorted large-cap stock - Hazeltree RE
Jefferies Adjusts Takeda Pharmaceutical's Price Target to 5,600 Yen From 5,200 Yen, Keeps at Buy MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,200 Yen From 5,300 Yen, Keeps at Buy MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,300 Yen From 5,100 Yen, Keeps at Buy MT
Jefferies Adjusts Takeda Pharmaceutical’s Price Target to 5,100 Yen From 5,000 Yen, Keeps at Buy MT
More recommendations

Press releases Takeda Pharmaceutical Company Limited

Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat AQ
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting BU
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K PU
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome BU
Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI) BU
More press releases

News in other languages on Takeda Pharmaceutical Company Limited

Pharmakonzern Takeda plant Abbau von bis zu 120 Stellen in Opfikon
Evotec steigt aus Gentherapie-Geschäft aus - Ergebniseinbruch zum Jahresstart
Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...
Takeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023, liefert Ausblick auf das GJ 2024, und bekräftigt Bekenntnis zur Pipeline-Entwicklung in der späten Entwicklungsphase sowie zur Steigerung der operativen Gewinnmarge
Takeda anuncia los resultados del año fiscal 2023 y sus perspectivas para el ejercicio 2024, reafirmando su compromiso con el desarrollo de productos en fase avanzada y la expansión del margen de beneficio operativo principal
More news

Quotes and Performance

1 month-5.01%
Current year+2.13%
More quotes

Highs and lows

1 month
4 080.00
Extreme 4080
4 435.00
3 years
3 175.00
Extreme 3175
4 435.00
5 years
2 990.00
Extreme 2990
4 500.00
More quotes

Managers and Directors - Takeda Pharmaceutical Company Limited

Managers TitleAgeSince
Christophe Weber CEO
 Chief Executive Officer 57 14-03-31
Gabriele Ricci CTO
 Chief Tech/Sci/R&D Officer 45 22-01-31
Mwana Lugogo CMP
 Compliance Officer 54 11-12-31
Members of the board TitleAgeSince
Yoshiaki Fujimori BRD
 Director/Board Member 71 16-05-31
Ian Clark BRD
 Director/Board Member 62 18-12-31
Steven Gillis BRD
 Director/Board Member 71 18-12-31
More insiders

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).
Sector
Pharmaceuticals
Calendar
2024-06-25 - Annual General Meeting
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,044 JPY
Average target price
4,768 JPY
Spread / Average Target
+17.90%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+52.38% 797B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.55% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.09% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.42% 323B
ABBVIE INC. Stock AbbVie Inc.
+10.69% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.13% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+1.39% 223B
AMGEN INC. Stock Amgen Inc.
+5.77% 163B
PFIZER, INC. Stock Pfizer, Inc.
-5.38% 153B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4502 Stock
  4. 4502 Stock